Categories: NewsPharmaceutical

Clene to Present at the Emerging Growth Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

Virtual Presentation Details
Date: June 12, 2024
Time of Presentation: 2:20 p.m. EDT
Format: Corporate presentation with Q&A

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1658205&tp_key=76d4029138&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.

About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Contacts:

Media Contact Investor Contact
Ignacio Guerrero-Ros, Ph.D., or David Schull Kevin Gardner
Russo Partners, LLC LifeSci Advisors
Ignacio.guerrero-ros@russopartnersllc.com kgardner@lifesciadvisors.com
David.schull@russopartnersllc.com 617-283-2856
(858) 717-2310  

Staff

Recent Posts

Genflow Biosciences PLC Announces Holding(s) in Company – 2

TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January…

2 hours ago

Genflow Biosciences PLC Announces Holding(s) in Company – 1

TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January…

2 hours ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

– Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency…

11 hours ago

MaryRuth’s Celebrates TikTok Shop Super Brand Day With Exclusive Offers and Viral Favorites

LOS ANGELES, Jan. 12, 2025 /PRNewswire/ -- MaryRuth's, the trusted leader in liquid vitamins and…

17 hours ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately…

20 hours ago

Lipozem: Introducing Lipozem as the Bizarre Turmeric Hack for Weight Loss Support

LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight…

20 hours ago